Results 71 to 80 of about 29,631 (205)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes

Reproductive BioMedicine Online, 2022
Do elective oocyte cryopreservation outcomes in women 1-13 months after SARS-CoV-2 vaccination alter compared with unvaccinated women and do different time intervals between vaccination and ovarian stimulation impact these outcomes?This retrospective cohort study, conducted in a university-affiliated IVF centre, included 232 elective oocyte ...
Gilad Karavani, Henry H. Chill, Aharon Dick, Cherut Meirman, Einat Gutman-Ido, Shmuel Herzberg, Assaf Ben-Meir, Tal Imbar   +7 more
openaire   +2 more sources

Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy

Vaccines, 2022
In the present study, antibody and T cell-mediated immune responses elicited by BBIBP-CorV and BNT162b2 vaccines were compared 6 months after the two-dose immunization of healthy individuals.
Zsolt Matula, Márton Gönczi, Gabriella Bekő, Béla Kádár, Éva Ajzner, Ferenc Uher, István Vályi-Nagy   +6 more
doaj   +1 more source

Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong

, 2022
BACKGROUND AND OBJECTIVE: Few head-to-head evaluations of immune responses to different vaccines have been reported. METHODS: Surrogate virus neutralization test (sVNT) antibody levels of adults receiving either two doses of BNT162b2 (n = 366) or ...
Bull, M, Cheng, SMS, Leung, DW, Dai, Z, Mok, CKP, Yiu, K, Wu, C, Lui, GCY, Amarasinghe, GK, Ng, SS, Cohen, CA, Wong, SYS, Valkenburg, SA, Chen, C, Hui, DS, Peiris, M, Chan, TO, Ling, KC, Kwok, KO   +18 more
core   +1 more source

Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy

BMC Rheumatology, 2023
Background The importance of COVID-19 vaccination for patients on immunosuppressive (IS) medication has increased due to the high risk of severe disease or mortality.
Fulya Cosan, Ozlem Unay Demirel, Demet Yalcin, Muhammed Mert Sonkaya, Isilsu Ezgi Uluisik, Olida Cecen, Yavuz Furuncuoglu, Deniz Maktav Celikmen, Osman Kara, Erkan Ceylan, Timucin Avsar   +10 more
doaj   +1 more source

Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies

Vaccines, 2022
Given the increasing anti-vaccine movements erroneously touting vaccine danger, this review has investigated the rare adverse events potentially associated with BNT162b2 (Pfizer-BioNTech), an mRNA vaccine against the severe acute respiratory distress ...
Shin-Jie Yong, Alice Halim, Michael Halim, Abbas Al Mutair, Saad Alhumaid, Jehad Al-Sihati, Hawra Albayat, Mohammed Alsaeed, Mohammed Garout, Reyouf Al Azmi, Noor Aldakheel, Abeer N. Alshukairi, Hani A. Al Ali, Adel A. Almoumen, Ali A. Rabaan   +14 more
doaj   +1 more source

Physical Characteristics of Injection Site Pain After COVID-19 mRNA BNT162b2 Vaccination [PDF]

Background: BNT162b2, an mRNA COVID-19 vaccine, was launched in many countries as an intramuscular vaccination for COVID-19 infection. Few studies have assessed the physical indications of pain at the immunization site.
Hasegawa, Junnichi, Ikeuchi, Tomoyuki, 70325009, 50343281, 100000112, Sugihara, Shuji, 16816, Yamasaki, Akira, Okada, Shinichi, 100000447, ヤマサキ, アキラ, Tomita, Katsuki, 4358, 16815, 16814, Touge, Hirokazu, 16813, 16812, 2857   +18 more
core   +1 more source

BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19

, 2021
BNT162b2 is a highly efficacious mRNA vaccine approved to prevent COVID-19. This brief report describes the immunogenicity and anti-viral protective effect of BNT162b2 in hACE2 transgenic mice.
Yumei Yang, Rui-Ru Ji, Chuan Qin, Hua Zhu, Ugur Sahin, Aimin Hui, Yajin Qu, Annette B. Vogel   +7 more
core   +1 more source

Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19

Acta Pharmaceutica, 2023
Abstract This retrospective observational study is aimed to determine the efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac (Sinovac) vaccines against symptomatic or severe disease in COVID-19-diagnosed patients.
Mustafa Dogan, Berna Yilmaz
openaire   +3 more sources

Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers

International Journal of Infectious Diseases, 2022
Objectives: There are limited comparative immunologic durability data post COVID-19 vaccinations. Methods: Approximately 8.4 months after primary COVID-19 vaccination, 647 healthcare workers completed surveys about COVID-19 vaccinations/infections and ...
Wendy M. Brunner, Daniel Freilich, Jennifer Victory, Nicole Krupa, Melissa B. Scribani, Paul Jenkins, Emily G. Lasher, Amanda Fink, Anshini Shah, Peggy Cross, Valerie Bush, Laura J. Peek, Gary A. Pestano, Anne M. Gadomski   +13 more
doaj   +1 more source

Impact of COVID‐19 and Vaccination on Lower Urinary Tract Symptoms: Insights From a Prospective Cohort Study

Neurourology and Urodynamics, EarlyView.
ABSTRACT Aims To evaluate the prevalence, clinical course, and risk factors of lower urinary tract symptoms (LUTS) in patients hospitalized with COVID‐19, and to assess associations with comorbidities, disease severity, and vaccination status. Methods We conducted a prospective cohort study of adult patients hospitalized with confirmed COVID‐19, who ...
Julia Duarte de Souza, Jose de Bessa Jr., Natássia Cristina Carboni Truzzi, Carolina Trigo Rocha, Bruno Camargo Rocha Paim de Araujo, Julyana Kanate Mazzoni Moromizato, Thulio Bosi Vieira Brandão, Rachel Mazoni Costa, Marcelo Hisano, Zein Mohamed Sammour, Homero Bruschini, William Carlos Nahas, Cristiano Mendes Gomes   +12 more
wiley   +1 more source